Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes.

Abrahami D, Douros A, Yin H, Yu OHY, Azoulay L.

Diabetes Care. 2019 Jul 11. pii: dc190849. doi: 10.2337/dc19-0849. [Epub ahead of print] No abstract available.

PMID:
31296645
2.

Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Adverse Cardiovascular Events: A Population-based Cohort Study.

Filion KB, Douros A, Azoulay L, Yin H, Yu OH, Suissa S.

Br J Clin Pharmacol. 2019 Jul 5. doi: 10.1111/bcp.14056. [Epub ahead of print]

PMID:
31276600
3.

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.

Klil-Drori AJ, Santella C, Tascilar K, Yin H, Aprikian A, Azoulay L.

Drug Saf. 2019 Aug;42(8):1005-1011. doi: 10.1007/s40264-019-00847-w.

PMID:
31240687
4.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.

Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L.

Diabetes Care. 2019 Jun 10. pii: dc190409. doi: 10.2337/dc19-0409. [Epub ahead of print]

PMID:
31182489
5.

Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism.

Santella C, Renoux C, Yin H, Yu OHY, Azoulay L.

Am J Epidemiol. 2019 May 30. pii: kwz138. doi: 10.1093/aje/kwz138. [Epub ahead of print]

PMID:
31145457
6.

Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study.

Loo SY, Azoulay L, Nie R, Dell'Aniello S, Yu OHY, Renoux C.

Am J Med. 2019 Apr 3. pii: S0002-9343(19)30281-5. doi: 10.1016/j.amjmed.2019.03.022. [Epub ahead of print]

PMID:
30953635
7.

Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study.

Rotshild V, Azoulay L, Feldhamer I, Perlman A, Muszkat M, Matok I.

Pharmacotherapy. 2019 Jun;39(6):690-696. doi: 10.1002/phar.2266. Epub 2019 Apr 17.

PMID:
30917404
8.

Risk of malignant cancers in inflammatory bowel disease.

Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P.

J Crohns Colitis. 2019 Mar 15. pii: jjz058. doi: 10.1093/ecco-jcc/jjz058. [Epub ahead of print]

PMID:
30874294
9.

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.

Douros A, Renoux C, Yin H, Filion KB, Suissa S, Azoulay L.

Am J Med. 2019 Feb;132(2):191-199.e12. doi: 10.1016/j.amjmed.2018.10.008. Epub 2018 Oct 25.

PMID:
30691551
10.

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10. No abstract available.

11.

Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers.

Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Raccah B, Horwitz E, Aldouby-Bier G, Negev T, Matok I, Azoulay L, Kalish Y, Muszkat M.

J Thromb Thrombolysis. 2019 May;47(4):590-595. doi: 10.1007/s11239-018-01804-7.

PMID:
30617727
12.

Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.

Montastruc F, Renoux C, Dell'Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S.

Rheumatology (Oxford). 2019 Apr 1;58(4):683-691. doi: 10.1093/rheumatology/key352.

PMID:
30535094
13.

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.

Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L.

BMJ. 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880.

14.

Calcium Channel Blockers and the Risk for Lung Cancer: A Population-Based Nested Case-Control Study.

Rotshild V, Azoulay L, Feldhamer I, Perlman A, Glazer M, Muszkat M, Matok I.

Ann Pharmacother. 2019 May;53(5):445-452. doi: 10.1177/1060028018814684. Epub 2018 Nov 15.

PMID:
30442036
15.

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Cancer. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13.

PMID:
30423211
16.

Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L.

BMJ. 2018 Oct 24;363:k4209. doi: 10.1136/bmj.k4209.

17.

Identification of incident pancreatic cancer in Ontario administrative health data: A validation study.

Wu JW, Azoulay L, Huang A, Paterson M, Wu F, Secrest MH, Filion KB.

Pharmacoepidemiol Drug Saf. 2018 Oct 4. doi: 10.1002/pds.4641. [Epub ahead of print]

PMID:
30288856
18.

A Comparison of Pathologic Outcomes of Open, Laparoscopic, and Robotic Resections for Rectal Cancer Using the ACS-NSQIP Proctectomy-Targeted Database: a Propensity Score Analysis.

Garfinkle R, Abou-Khalil M, Bhatnagar S, Wong-Chong N, Azoulay L, Morin N, Vasilevsky CA, Boutros M.

J Gastrointest Surg. 2019 Feb;23(2):348-356. doi: 10.1007/s11605-018-3974-8. Epub 2018 Sep 27.

PMID:
30264386
19.

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.

Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L.

Diabetes Care. 2018 Nov;41(11):2330-2338. doi: 10.2337/dc17-2280. Epub 2018 Aug 27.

PMID:
30150234
20.

Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.

Douros A, Abrahami D, Yin H, Yu OHY, Renoux C, Hudson M, Azoulay L.

Epidemiology. 2018 Nov;29(6):904-912. doi: 10.1097/EDE.0000000000000891.

PMID:
30028343
21.

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S.

BMJ. 2018 Jul 18;362:k2693. doi: 10.1136/bmj.k2693.

22.

Risk of Bias in Study of Varenicline and Cardiovascular Outcomes.

Goulden R, Nguyen QD, Azoulay L.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):690-691. doi: 10.1164/rccm.201803-0423LE. No abstract available.

PMID:
29708402
23.

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.

Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L.

BMJ. 2018 Mar 21;360:k872. doi: 10.1136/bmj.k872.

24.

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury.

Douros A, Azoulay L, Yin H, Suissa S, Renoux C.

J Am Coll Cardiol. 2018 Mar 13;71(10):1105-1113. doi: 10.1016/j.jacc.2018.01.009.

25.

The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.

Rotshild V, Azoulay L, Zarifeh M, Masarwa R, Hirsh-Raccah B, Perlman A, Muszkat M, Matok I.

Drug Saf. 2018 Jun;41(6):555-564. doi: 10.1007/s40264-018-0644-4. Review.

PMID:
29484611
26.

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.

Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB.

Acta Diabetol. 2018 May;55(5):503-514. doi: 10.1007/s00592-018-1116-0. Epub 2018 Feb 27. Review.

PMID:
29484489
27.

Reply to P. Autier et al.

Suissa S, Azoulay L.

J Clin Oncol. 2018 Mar 10;36(8):831-832. doi: 10.1200/JCO.2017.77.0057. Epub 2018 Jan 25. No abstract available.

PMID:
29369706
28.

Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.

Abrahami D, Yin H, Yu OHY, Pollak MN, Azoulay L.

Epidemiology. 2018 Mar;29(2):246-253. doi: 10.1097/EDE.0000000000000793.

PMID:
29283894
29.

Testosterone replacement therapy and the risk of stroke in men: A systematic review.

Loo SY, Chen BY, Yu OHY, Azoulay L, Renoux C.

Maturitas. 2017 Dec;106:31-37. doi: 10.1016/j.maturitas.2017.08.013. Epub 2017 Sep 1. Review.

PMID:
29150164
30.

Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.

Yu O, Azoulay L, Yin H, Filion KB, Suissa S.

Am J Med. 2018 Mar;131(3):317.e11-317.e22. doi: 10.1016/j.amjmed.2017.09.044. Epub 2017 Oct 12.

PMID:
29032229
31.

Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.

Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S.

J Clin Oncol. 2017 Nov 10;35(32):3647-3653. doi: 10.1200/JCO.2017.73.4491. Epub 2017 Sep 27.

PMID:
28953430
32.

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.

Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S.

Diabetes Care. 2017 Nov;40(11):1506-1513. doi: 10.2337/dc17-0595. Epub 2017 Sep 1.

PMID:
28864502
33.

Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.

Davidson MA, Mattison DR, Azoulay L, Krewski D.

Crit Rev Toxicol. 2018 Jan;48(1):52-108. doi: 10.1080/10408444.2017.1351420. Epub 2017 Aug 17.

PMID:
28816105
34.

Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer.

Hicks BM, Klil-Drori AJ, Yin H, Campeau L, Azoulay L.

Epidemiology. 2017 Sep;28(5):712-718. doi: 10.1097/EDE.0000000000000678.

PMID:
28768300
35.

A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer.

Taussky D, Souliéres D, Azoulay L, Yin H, Bahig H, Bahary JP, Delouya G.

Target Oncol. 2017 Oct;12(5):695-701. doi: 10.1007/s11523-017-0516-3.

PMID:
28712059
36.

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group.

Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. No abstract available.

37.

Postoperative Pelvic Radiotherapy in Patients With Endometrial Cancer May Increase the Risk for Secondary Pelvic Cancers: A Post Hoc Analysis of Results From the TME, PORTEC-1, and PORTEC-2 Trials.

Wissing MD, Azoulay L.

J Clin Oncol. 2017 Jun 1;35(16):1861-1862. doi: 10.1200/JCO.2017.72.6497. Epub 2017 Mar 13. No abstract available.

PMID:
28549230
38.

Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study.

Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, Batist G, Azoulay L, Kavan P.

Clin Colorectal Cancer. 2017 Dec;16(4):334-342. doi: 10.1016/j.clcc.2017.03.008. Epub 2017 Mar 21.

PMID:
28462853
39.

Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.

Azoulay L, Suissa S.

Diabetes Care. 2017 May;40(5):706-714. doi: 10.2337/dc16-1943. Review.

PMID:
28428321
40.

Metformin and the incidence of viral associated cancers in patients with type 2 diabetes.

Hicks BM, Yin H, Sinyavskaya L, Suissa S, Azoulay L, Brassard P.

Int J Cancer. 2017 Jul 1;141(1):121-128. doi: 10.1002/ijc.30733. Epub 2017 Apr 24.

41.

Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer.

Klil-Drori AJ, Yin H, Abenhaim HA, du Fort GG, Azoulay L.

J Clin Psychiatry. 2017 Jun;78(6):714-719. doi: 10.4088/JCP.15m10532.

PMID:
28199787
42.

A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada.

Greenaway C, Azoulay L, Allard R, Cox J, Tran VA, Abou Chakra CN, Steele R, Klein M.

BMC Infect Dis. 2017 Feb 13;17(1):140. doi: 10.1186/s12879-017-2242-y.

43.

Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia.

Hicks BM, Yin H, Bladou F, Ernst P, Azoulay L.

Thorax. 2017 Jul;72(7):596-597. doi: 10.1136/thoraxjnl-2016-209512. Epub 2016 Dec 16.

PMID:
27986803
44.

Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.

Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L.

J Clin Oncol. 2017 Jan 10;35(2):201-207. Epub 2016 Nov 21.

PMID:
27870566
45.

The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.

Mandilaras V, Bouganim N, Yin H, Asselah J, Azoulay L.

Br J Cancer. 2017 Jan 3;116(1):103-108. doi: 10.1038/bjc.2016.375. Epub 2016 Nov 15.

46.

Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

Klil-Drori AJ, Azoulay L, Pollak MN.

Nat Rev Clin Oncol. 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9. Review.

PMID:
27502359
47.
49.

The Use of Telmisartan and the Incidence of Cancer.

Tascilar K, Azoulay L, Dell'Aniello S, Bartels DB, Suissa S.

Am J Hypertens. 2016 Dec 1;29(12):1358-1365. doi: 10.1093/ajh/hpw095.

50.

Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec.

Kamstra R, Azoulay L, Steele R, Klein MB, Greenaway C.

Clin Infect Dis. 2016 Dec 1;63(11):1439-1448. Epub 2016 Aug 7.

PMID:
27501843

Supplemental Content

Loading ...
Support Center